Skip to content
Home › 13F recaps › Q3 2026 › TWST

Which funds bought or sold TWST in Q3 2026?

Twist Bioscience Corp. 5 funds bought, 3 sold, out of 109 tracked funds that have filed for Q3 2026. Among active managers, the estimated net flow was +$673M. See also what famous investors say about TWST.

Holdings as of Sep 30, 2026 (Q3 2026)13F deadline Nov 16, 2026 (45 days after quarter end)

PostLinkedIn
Who bought and who sold TWST, by estimated dollars
◀ SoldBought ▶

Top 10 each side. NEW = opened a position, OUT = sold the whole position.

Bought (5)

FundChangeEst. $Now
Fidelity
Asset manager
Added+106.2%+$965M$1.9B
D. E. Shaw
Quant & multi-strategy
Added+54%+$124M$353M
Vanguard Capital
Index giant
Added+10.3%+$54M$575M
Durable
Growth / crossover
New+$49M$49M
Polen
Growth / crossover
Added+46.9%+$5M$16M

Sold (3)

FundChangeEst. $Now
ARK
Growth / crossover
Trimmed-25.3%−$223M$657M
Baillie Gifford
Growth / crossover
Trimmed-34.9%−$73M$137M
Jennison
Growth / crossover
Trimmed-56.6%−$50M$38M

Source: SEC EDGAR Form 13F-HR for each fund, holdings as of Sep 30, 2026. Shares only (options excluded). Estimated $ = change in shares × quarter-end price. Funds may have traded since. Methodology. Not investment advice.

Most bought in Q3 2026 → · Most sold →

Weekly digest · free

13F filings and guru moves, in one short email

A Sunday digest of what famous investors said and filed this week, plus an alert when someone changes stance. Free, no spam, unsubscribe anytime.